Core Viewpoint - Clearmind Medicine Inc. has announced the publication of six patents in Hong Kong, focusing on innovative combination therapies that integrate Palmitoylethanolamide (PEA) with various psychedelic compounds to address under-treated health issues [1][2][3] Group 1: Patent Publication and Innovations - The newly published patents protect formulations that combine PEA with MDMA, LSD, Ketamine, Ibogaine, Psilocybin, and DMT, aiming to enhance therapeutic potential and improve safety and tolerability for mental health and neurological conditions [2] - The company currently holds a total of nineteen patent families, which include 31 granted patents, and plans to seek additional patents as opportunities arise [5] Group 2: Company Strategy and Objectives - Clearmind is focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics to tackle significant health problems, including alcohol use disorder [4] - The CEO emphasized the strategic combination of PEA with well-characterized psychedelics to build a robust pipeline of next-generation candidates aimed at addressing unmet needs in mental health [3]